IGC Pharma, Inc. (IGC) shareholders
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/309% above fair value
$0.18−0.01 (-4.61%)
Close on Nov 13, 2026Market cap $18.20MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.1%
5M of 103M shares
Institutional holders
36
7 new, 4 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bradbury Strategic Investment Fund A | 13,823,529 | 18.30% | 13D (active) amendment | Mar 22, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IGC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 879,394 | 0.85% | $239.23K | −163,990 | 0.00% |
| Vanguard Capital Management LLC | 814,914 | 0.79% | $221.66K | +96,478 | 0.00% |
| BlackRock, Inc. | 703,798 | 0.68% | $191.43K | – | 0.00% |
| AdvisorShares Investments LLC | 678,480 | 0.66% | $184.55K | New | 0.02% |
| Citadel Advisors LLC | 437,317 | 0.42% | $118.95K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 419,413 | 0.41% | $114.08K | +3,525 | 0.00% |
| Renaissance Technologies LLC | 286,608 | 0.28% | $77.96K | −197,367 | 0.00% |
| State Street Corp | 200,799 | 0.19% | $54.62K | – | 0.00% |
| Northern Trust Corp | 170,274 | 0.16% | $46.32K | +56,867 | 0.00% |
| Dearborn Partners LLC | 118,802 | 0.11% | $31.78K | +59,401 | 0.00% |
| Lawood & Co | 75,000 | 0.07% | $20.40K | – | 0.01% |
| Goldman Sachs Group Inc | 65,541 | 0.06% | $17.83K | – | 0.00% |
| Jane Street Group, LLC | 62,610 | 0.06% | $17.03K | New | 0.00% |
| Truist Financial Corp | 48,667 | 0.05% | $13.24K | +12,000 | 0.00% |
| Citigroup Inc | 46,043 | 0.04% | $12.52K | New | 0.00% |
| Fisher Asset Management, LLC | 43,400 | 0.04% | $11.80K | – | 0.00% |
| XTX Topco Ltd | 39,378 | 0.04% | $10.71K | −11,270 | 0.00% |
| Morgan Stanley | 35,198 | 0.03% | $9.57K | +80 | 0.00% |
| Commonwealth Equity Services, LLC | 33,348 | 0.03% | $9.07K | −500 | 0.00% |
| Susquehanna International Group, Llp | 28,882 | 0.03% | $7.86K | −93,713 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 36 | 5M | 5.1% | 7 / 7 | 7 / 4 | 1M | 1M |
| Q1 2026 | 35 | 4M | 4.2% | 11 / 6 | 5 / 4 | 1M | 1M |
| Q4 2025 | 30 | 5M | 4.7% | 5 / 5 | 5 / 9 | 0M | 1M |
| Q3 2025 | 35 | 5M | 5.3% | 9 / 8 | 4 / 2 | 2M | 0M |
| Q2 2025 | 28 | 3M | 2.9% | 5 / 6 | 5 / 2 | 0M | 0M |
| Q1 2025 | 25 | 3M | 2.8% | 1 / 6 | 5 / 6 | 0M | 0M |
| Q4 2024 | 30 | 3M | 2.7% | 9 / 5 | 7 / 2 | 0M | 0M |
| Q3 2024 | 23 | 3M | 2.7% | 3 / 9 | 2 / 4 | 1M | 0M |
| Q2 2024 | 25 | 3M | 2.5% | 5 / 4 | 7 / 5 | 0M | 0M |
| Q1 2024 | 25 | 2M | 2.3% | 6 / 3 | 5 / 6 | 0M | 0M |
| Q4 2023 | 25 | 2M | 2.4% | 5 / 5 | 5 / 7 | 0M | 0M |
| Q3 2023 | 27 | 3M | 2.7% | 4 / 7 | 6 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held IGC in Q2 2026, 64% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IGC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 814,914 | 0.79% | $221.66K | 0.00% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 678,480 | 0.66% | $184.55K | 0.42% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 630,022 | 0.61% | $182.01K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 98,554 | 0.10% | $28.47K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 95,369 | 0.09% | $27.55K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ram Mukunda | CEO, Director | 7,652,982 | 7.40% | Sep 29, 2026 |
| Claudia Grimaldi | PFO, Director | 3,271,092 | 3.16% | Sep 29, 2026 |
| Richard K. Prins | Director | 1,541,251 | 1.49% | Apr 6, 2026 |
| James P. Moran | Director | 2,128,137 | 2.06% | Apr 6, 2026 |
| Terry L. Lierman | Director | 29,411 | 0.03% | Oct 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Claudia Grimaldi PFO, Director | Sep 25, 2026 | Gift | −150,000 | – | – | 3,271,092 |
| Ram Mukunda CEO, Director | Sep 25, 2026 | Gift | −100,000 | – | – | 6,775,563 |
| Ram Mukunda CEO, Director | Sep 25, 2026 | Gift | −100,000 | – | – | 6,675,563 |
| Claudia Grimaldi PFO, Director | Jun 30, 2026 | Award | +2,048,378 | $0.27 | $553.06K | 3,421,092 |
| Ram Mukunda CEO, Director | Jun 30, 2026 | Award | +2,226,475 | $0.27 | $601.15K | 6,875,563 |
| Richard K. Prins Director | Apr 1, 2026 | Option exercise | +70,000 | – | – | 1,541,251 |
| Richard K. Prins Director | Apr 1, 2026 | Option exercise | +100,000 | – | – | 1,471,251 |
| James P. Moran Director | Apr 1, 2026 | Option exercise | +80,000 | – | – | 1,185,735 |
| James P. Moran Director | Apr 1, 2026 | Option exercise | +50,000 | – | – | 1,235,735 |
| Ram Mukunda CEO, Director | Apr 1, 2026 | Option exercise | +333,333 | – | – | 4,326,011 |
| Ram Mukunda CEO, Director | Apr 1, 2026 | Option exercise | +323,077 | $0.26 | $84.00K | 4,649,088 |
| Ram Mukunda CEO, Director | Apr 1, 2026 | Option exercise | +16,667 | – | – | 877,419 |
| Ram Mukunda CEO, Director | Apr 1, 2026 | Option exercise | +33,332 | – | – | 910,751 |
| Claudia Grimaldi PFO, Director | Apr 1, 2026 | Option exercise | +100,000 | – | – | 1,234,252 |
| Claudia Grimaldi PFO, Director | Apr 1, 2026 | Option exercise | +138,462 | $0.26 | $36.00K | 1,372,714 |
| Ram Mukunda CEO, Director | Feb 3, 2026 | Option exercise | +50,000 | – | – | 860,752 |
| Richard K. Prins Director | Jan 19, 2026 | Option exercise | +100,000 | – | – | 1,371,251 |
| Claudia Grimaldi PFO, Director | Oct 17, 2025 | Gift | −50,000 | – | – | 1,134,252 |
| Ram Mukunda CEO, Director | Oct 17, 2025 | Gift | −100,000 | – | – | 3,992,678 |
| Richard K. Prins Director | Mar 31, 2025 | Option exercise | +70,000 | – | – | 1,271,251 |
| Richard K. Prins Director | Mar 31, 2025 | Option exercise | +100,000 | – | – | 1,201,251 |
| Richard K. Prins Director | Mar 31, 2025 | Option exercise | +58,333 | – | – | 1,101,251 |
| Claudia Grimaldi Director | Mar 31, 2025 | Option exercise | +58,333 | – | – | 1,084,252 |
| Claudia Grimaldi Director | Mar 31, 2025 | Option exercise | +100,000 | – | – | 1,184,252 |
| Ram Mukunda CEO, Director | Mar 31, 2025 | Option exercise | +233,333 | – | – | 3,759,345 |
| Ram Mukunda CEO, Director | Mar 31, 2025 | Option exercise | +333,333 | – | – | 4,092,678 |
| James P. Moran Director | Mar 31, 2025 | Option exercise | +33,333 | – | – | 975,735 |
| James P. Moran Director | Mar 31, 2025 | Option exercise | +80,000 | – | – | 1,055,735 |
| James P. Moran Director | Mar 31, 2025 | Option exercise | +50,000 | – | – | 1,105,735 |
| James P. Moran Director | Sep 25, 2024 | Buy | +588,235 | $0.34 | $200.00K | 942,402 |
| Richard K. Prins Director | Aug 12, 2024 | Gift | −200,000 | – | – | 1,042,917 |
| Strategic Investment Fund A. (Cayman Islands Registration No. CR-359857) Bradbury 10% owner | Mar 22, 2024 | Award | +8,823,529 | $0.34 | $3.00M | 13,823,529 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Option exercise | +333,333 | – | – | 2,908,093 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Option exercise | +233,334 | – | – | 3,141,427 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Option exercise | +333,334 | – | – | 3,474,761 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Gift | −200,000 | – | – | 3,526,011 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Option exercise | +16,667 | – | – | 794,085 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Option exercise | +16,667 | – | – | 810,752 |
| Ram Mukunda CEO, Director | Mar 13, 2024 | Option exercise | +251,250 | – | – | 3,726,011 |
| James P. Moran Director | Mar 13, 2024 | Option exercise | +29,000 | – | – | 354,167 |
| James P. Moran Director | Mar 13, 2024 | Option exercise | +50,000 | – | – | 183,334 |
| James P. Moran Director | Mar 13, 2024 | Option exercise | +33,334 | – | – | 216,667 |
| James P. Moran Director | Mar 13, 2024 | Option exercise | +80,000 | – | – | 296,667 |
| James P. Moran Director | Mar 13, 2024 | Option exercise | +28,500 | – | – | 325,167 |
| Claudia Grimaldi Director | Mar 13, 2024 | Option exercise | +58,333 | – | – | 842,154 |
| Claudia Grimaldi Director | Mar 13, 2024 | Option exercise | +100,000 | – | – | 942,154 |
| Claudia Grimaldi Director | Mar 13, 2024 | Option exercise | +95,000 | – | – | 1,037,154 |
| Claudia Grimaldi Director | Mar 13, 2024 | Option exercise | +83,333 | – | – | 783,821 |
| Richard K. Prins Director | Mar 13, 2024 | Option exercise | +58,333 | – | – | 1,071,667 |
| Richard K. Prins Director | Mar 13, 2024 | Option exercise | +100,000 | – | – | 1,013,334 |
| Richard K. Prins Director | Mar 13, 2024 | Option exercise | +28,500 | – | – | 1,242,917 |
| Richard K. Prins Director | Mar 13, 2024 | Option exercise | +42,750 | – | – | 1,214,417 |
| Richard K. Prins Director | Mar 13, 2024 | Option exercise | +100,000 | – | – | 1,171,667 |
| Ram Mukunda CEO, Director | Jun 23, 2023 | Gift | −400,000 | – | – | 3,174,761 |
| Claudia Grimaldi VICE PRESIDENT, CCO & PF0 | Mar 31, 2023 | Option exercise | +58,334 | – | – | 700,488 |
| Claudia Grimaldi VICE PRESIDENT, CCO & PF0 | Mar 31, 2023 | Option exercise | +83,333 | – | – | 642,154 |
| James P. Moran Director | Mar 31, 2023 | Option exercise | +33,334 | – | – | 133,334 |
| James P. Moran Director | Mar 31, 2023 | Option exercise | +50,000 | – | – | 100,000 |
| Ram Mukunda CEO, Director | Mar 31, 2023 | Option exercise | +16,667 | – | – | 760,751 |
| Ram Mukunda CEO, Director | Mar 31, 2023 | Option exercise | +16,667 | – | – | 777,418 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.44%
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
-37.8%
From 1M shares
Short volume, 20 days
33.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IGC Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 587,489 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard K. Prins Director | Aug 9, 2024 | 200,000 | $78.20K | Aug 12, 2024 | Restricted Stock Award |
| Ram Mukunda Officer | Mar 15, 2024 | 300,000 | $600.00K | Mar 15, 2024 | Shares granted from ESOP and special grant (approved by shareholders on Sept 12, 2014) |
See a number that looks wrong?